MungallDRAnbeDForresterPLLuomaTGenoveseRMahanJ. A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram—directed heparin therapy. Clin Pharmacol Ther1994; 55: 591–6.
2.
BoneuBCaranobeCGabaigAMDupouyDSiePBuchananMR. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res1987; 46: 835–44.
3.
KandrotasRJGalPDouglasJBDeterdingJ. Heparin pharmacokinetics during hemodialysis. Ther Drug Monit1989; 11: 674–9.
4.
KandrotasRJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet1992; 22: 359–74.
5.
Brill-EdwardsPGinsbergJSJohnstonMHirshJ. Establishing a therapeutic range for heparin therapy. Ann Intern Med1993; 119: 104–9.
6.
BrandtJTTriplettDA. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol1981; 76 (suppl): 530–7.
7.
BanezEITriplettDAKoepkeJ. Laboratory monitoring of heparin therapy—the effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol1980; 74: 569–74.
8.
BainBForsterTSleighB. Heparin and the activated partial thromboplastin time—a difference between the in vitro and in vivo effects and implications for the therapeutic range. Am J Clin Pathol1980; 74: 668–73.
9.
HolmHA. Amidolytic heparin assay (Coatest Heparin) and correlation to clinical effects in heparin treatment of deep venous thrombosis (DVT). Acta Chir Scand1982; 509 (suppl):115–6.
10.
TurpieAGRobinsonJGDoyleDJMuljiASMishkelGJSealyBJ. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute trans-mural anterior myocardial infarction. N Engl J Med1989; 320: 352–7.
11.
LevineMNHirshJGentMTurpieAGCruickshankMWeitzJ. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med1994; 154: 49–56.
12.
StiekemaJCJVan GriensvenJMTVan DintherTGCohenAF. A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan. Br J Clin Pharmacol1993; 36: 51–6.
McGarryTFGottliebRSMorganrothJZelenkofskeSLKasparianHDucaPR. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J1992; 123: 1445–51.
15.
GrillHPSperoJEGranatoJE. Comparison of activated partial thromboplastin time to activated clotting time for adequacy of heparin anticoagulation just before percutaneous transluminal coronary angioplasty. Am J Cardiol1993; 71: 1219–20.
16.
MungallDFloydR. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol1989; 29: 1043–7.
